Active immunotherapy

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, May 16, 2023
US Foods, MHC, Cancer, SITC, Immunotherapy, Statistics, ASX, Fast Track, NSCLC, Lung cancer, TPS, IMM, Active immunotherapy, MHC class II, Patient, Autoimmune disease, Immutep, Phase, FDA, Pembrolizumab, Food, Pharmaceutical industry

SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the US Food and Drug Administration (FDA), regarding the Company’s late-stage clinical development plans for its first-in-class soluble LAG-3 protein and MHC Class II agonist, eftilagimod alpha (“efti”), for the treatment of 1st line non-small cell lung cancer (NSCLC).

Key Points: 
  • SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the US Food and Drug Administration (FDA), regarding the Company’s late-stage clinical development plans for its first-in-class soluble LAG-3 protein and MHC Class II agonist, eftilagimod alpha (“efti”), for the treatment of 1st line non-small cell lung cancer (NSCLC).
  • This trial will be named TACTI-004 (Two ACTive Immunotherapies).
  • Immutep CEO, Marc Voigt, commented: “In light of our compelling clinical data that efti has generated in combination with anti-PD-1 therapy, this meeting with the FDA is a critical step in our late-stage development process for 1st line non-small cell lung cancer.
  • We are thankful for the positive feedback as we continue moving forward with our unique immuno-oncology approach for the many cancer patients impacted by this difficult disease.”
    Immutep CSO, Dr. Frédéric Triebel, stated: “We are very pleased with our constructive dialogue with the FDA establishing a clear path forward for efti in front line non-small cell lung cancer.

Immutep Quarterly Activities Report

Retrieved on: 
Thursday, April 27, 2023
Amgen, Institutional review board, European Medicines Agency, G&A, Rated R, Patent, Patient, NSW, Acceleration, Disease, CSO, Lung cancer, EMA, Related party transaction, Global Medical Device Nomenclature, PD-1, Phase, FDA, Death, Safety, Health care, MHC, Cancer, NSCLC, CMO, Immunotherapy, PFS, US, IRB, Grant, Pembrolizumab, Therapy, Family, ORR, Kinetics, Infection, Doctor of Philosophy, Progression-free survival, Clinical trial, OS, Paclitaxel, ASX, B cell, Part, ELCC, Marketing, Caliper Life Sciences, IMM, MHC class II, Novartis, APC, Active immunotherapy, Breast cancer, Palladium, Pharmaceutical industry, Vaccine, Cryptocurrency, Immutep

SYDNEY, AUSTRALIA, April 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 March 2023 (Q3 FY23).

Key Points: 
  • Subsequent to quarter end TACTI-003 has reached 75% enrolment, and Immutep expects to complete enrolment by mid-year positioning the Company to report top-line results in H2 of CY2023.
  • The net cash used in R&D activities in the quarter was A$11.52 million, compared to A$5.87 million in Q2 FY23.
  • Total net cash outflows used in operating activities in the quarter were A$14.17 million compared to A$7.02 million in Q2 FY23.
  • Immutep will continue to manage its solid cash balance carefully as it pursues its overall clinical development strategy.

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

Retrieved on: 
Tuesday, March 14, 2023
AIPAC, EMA, Cancer, Monocyte, Glomus tumor, Breast cancer, MHC, Science, CD8, Paclitaxel, IRB, Survival, Active immunotherapy, IMM, Institutional review board, MHC class II, OS, Marketing Authorisation Application, Phase, IO, MAA, Autoimmune disease, APC, Patient, MOS, Triple-negative breast cancer, B cell, FDA, US Foods, NSCLC, TNBC, European Medicines Agency, MBC, ORR, Calendar, BLA, Quality of life, Safety, HNSCC, Food, Biologics license application, ASX, HIV disease progression rates, Pharmaceutical industry

SYDNEY, AUSTRALIA, March 14, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (“efti”) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC). Regulatory approval has been received in the US and Institutional Review Board (IRB) approval has been received in Spain, with approvals in additional countries anticipated to follow shortly. The first patient is expected to be enrolled in early Q2 CY2023.

Key Points: 
  • As a first-in-class soluble LAG-3 protein targeting MHC Class II ligands on antigen-presenting cells (APC), efti is uniquely positioned to improve clinical outcomes from standard-of-care chemotherapy.
  • Based on feedback from the FDA/EMA, the HR+/HER2-neg/low MBC patient population has been expanded to include triple-negative breast cancer (TNBC), an aggressive cancer with limited treatment options, which together account for ~78% of breast cancer cases.
  • Depending on the Phase II results, potential regulatory actions and resources, a randomized, double-blinded, placebo-controlled Phase III portion will then follow.
  • The Phase III will have overall survival as the primary objective and may include a specific patient population.

CancerVAX Announces Research Program to Develop Its First Immunotherapy Cancer Treatment

Retrieved on: 
Wednesday, May 26, 2021
Medicine, Clinical medicine, CancerVax, Branches of biology, Immunotherapy, Sarcoma, Cancer, Treatment of cancer, Active immunotherapy, Antoni Ribas

The program will focus on developing effective immunotherapies such as CAR T-cell and custom antibodies for Ewing sarcoma.

Key Points: 
  • The program will focus on developing effective immunotherapies such as CAR T-cell and custom antibodies for Ewing sarcoma.
  • This program expands on the preliminary laboratory work done at UCLA by leveraging outside commercial-grade immunotherapy development processes and services.
  • CancerVAX, Inc. is developing immunotherapy cancer treatments that use the bodys immune system to fight cancer.
  • Our research is performed at the UCLA Jonsson Comprehensive Cancer Center by a leading cancer research team.

Gamma Delta T Cell Cancer Therapy Market To Transform Cancer Immunotherapy Landscape

Retrieved on: 
Friday, April 23, 2021
Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, T cells, Immune system, Immunotherapy, Chimeric antigen receptor T cell, Bispecific monoclonal antibody, Gamma delta T cell, Active immunotherapy, David G. Maloney

b'Commercialization Market Potential After Market Launch: > USD 4 Billion\nGamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies\nIn recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies.

Key Points: 
  • b'Commercialization Market Potential After Market Launch: > USD 4 Billion\nGamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies\nIn recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies.
  • To overcome this, research is now focusing on exploiting rate type of gamma delta T cells in cancer immunotherapy.
  • Presently, researchers have designed gamma delta chimeric antigen receptor and bispecific antibodies targeting the gamma delta T cell to generate anti-tumor response in wide range of tumors.
  • Moreover, it is expected that coming years will witness a wide range of combinational therapy using gamma delta T cell therapy will emerge to manage the complexity of cancer.\nIt is expected that North America followed by Europe will dominate the global gamma delta T cell therapeutics market due to the high adoption rates of novel cancer immunotherapy in this region and the high prevalence of cancer.

Gamma Delta T Cell Cancer Therapy Market To Transform Cancer Immunotherapy Landscape

Retrieved on: 
Friday, April 23, 2021
Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, Immune system, Immunotherapy, Chimeric antigen receptor T cell, Bispecific monoclonal antibody, Active immunotherapy, David G. Maloney

b'- Gamma Delta T Cell Cancer Therapy to give New Horizon to Cancer Immunotherapy Market, Says Kuick Research\nCommercialization Market Potential After Market Launch: > USD 4 Billion\nGamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies\nIn recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies.

Key Points: 
  • b'- Gamma Delta T Cell Cancer Therapy to give New Horizon to Cancer Immunotherapy Market, Says Kuick Research\nCommercialization Market Potential After Market Launch: > USD 4 Billion\nGamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies\nIn recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies.
  • To overcome this, research is now focusing on exploiting rate type of gamma delta T cells in cancer immunotherapy.
  • Presently, researchers have designed gamma delta chimeric antigen receptor and bispecific antibodies targeting the gamma delta T cell to generate anti-tumor response in wide range of tumors.
  • Moreover, it is expected that coming years will witness a wide range of combinational therapy using gamma delta T cell therapy will emerge to manage the complexity of cancer.\nIt is expected that North America followed by Europe will dominate the global gamma delta T cell therapeutics market due to the high adoption rates of novel cancer immunotherapy in this region and the high prevalence of cancer.

Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit

Retrieved on: 
Thursday, March 25, 2021
Medical specialties, Clinical medicine, Medicine, Virotherapy, Immune system, Immunology, Cancer immunotherapy, Immunotherapy, Cytokine, Programmed cell death protein 1, Active immunotherapy

The presentation will take place today, March 25, 2021 at 2:25 pm ET at the virtual Cytokine-Based Cancer Immunotherapies Summit.

Key Points: 
  • The presentation will take place today, March 25, 2021 at 2:25 pm ET at the virtual Cytokine-Based Cancer Immunotherapies Summit.
  • New data show that MDNA11 monotherapy or when combined with anti-PD-1 therapy stimulated potent immune responses in preclinical tumor models highlighting the potential of our Superkine platform to address this need.
  • We plan to present additional data on our IL-2/IL-13 dual specific cytokine next month, which may further validate the versatility of our Superkine platform.
  • Those interested in viewing the live presentation or participating in the Q&A session can register for the Cytokine-Based Cancer Immunotherapies Summit here .

PDS Biotech Announces Presentation and Panel Participation at the Benzinga Biotech Small Cap Conference

Retrieved on: 
Wednesday, March 17, 2021
Clinical medicine, Medicine, Virotherapy, Cancer immunotherapy, Immunotherapy, Immune system, Active immunotherapy

In addition, Dr. Bedu-Addo will participate in the "Cancer Immunotherapies: Fighting Cancer with the power of the Immune System" panel immediately following his presentation at 10:25am ET on Wednesday, March 24.

Key Points: 
  • In addition, Dr. Bedu-Addo will participate in the "Cancer Immunotherapies: Fighting Cancer with the power of the Immune System" panel immediately following his presentation at 10:25am ET on Wednesday, March 24.
  • A replay of the Company's presentation will be available online in the investor relations section of the Company's website for 90 days following the event.
  • PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune T-cell activating technology platform.
  • PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

NexImmune to Present at the 2021 Barclays Global Healthcare Conference

Retrieved on: 
Tuesday, March 2, 2021
Medical specialties, Clinical medicine, Branches of biology, Immunology, Immune system, Cancer immunotherapy, Immunotherapy, Virotherapy, Immunoglobulin E, T cell, Cancer vaccine, Active immunotherapy

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced thatScott Carmer, Chief Executive Officer, will present a company overview at thevirtual 2021 Barclays Global Healthcare Conference onThursday, March 11, 2021at10:55 a.m. Eastern time.

Key Points: 
  • GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced thatScott Carmer, Chief Executive Officer, will present a company overview at thevirtual 2021 Barclays Global Healthcare Conference onThursday, March 11, 2021at10:55 a.m. Eastern time.
  • The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations .
  • A replay will be available on the NexImmune website following the presentation.
  • NexImmune, based inGaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology.

NEUVOGEN Announces Participation at B. Riley Virtual Oncology Investor Conference

Retrieved on: 
Wednesday, January 20, 2021
Medical specialties, Clinical medicine, Medicine, Vaccination, Oncology, Cancer vaccine, Immunotherapy, Immune system, Tumor antigen, Vaccine, Tumor antigen vaccine, Active immunotherapy

SAN DIEGO, Jan. 20, 2021 /PRNewswire/ --NEUVOGEN todayannounced that Todd Binder, Chief Executive Officer of NEUVOGEN, will participate in the B. Riley Virtual Oncology Investor Conference:

Key Points: 
  • SAN DIEGO, Jan. 20, 2021 /PRNewswire/ --NEUVOGEN todayannounced that Todd Binder, Chief Executive Officer of NEUVOGEN, will participate in the B. Riley Virtual Oncology Investor Conference:
    NEUVOGEN, Inc. is an immunoncology company focused on whole cell cancer vaccine therapies.
  • NEUVOGEN's immunotherapies have the potential to deliver the broadest ever combination of tumor antigens to prime immune response.
  • Based in San Diego, California, NEUVOGEN's goal is to bring to market a pipeline of therapeutic cancer vaccines that activate the body's immune system to eradicate solid tumors and meaningfully extend the lives of patients while limiting side effects generally associated with traditional cancer treatments.
  • To learn more, visit www.neuvogen.com